Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term DYD-301 study in Japanese patients with Lambert-Eaton myasthenic syndrome
jRCT2031210552Completed
- Sponsor
- DyDo Pharma,Inc.
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of amifampridine in Lambert-Eaton myasthenic syndrome (LEMS), sponsored by DyDo Pharma,Inc. Primary endpoint: Change from baseline in QMG total score at Visit 6. Started Mar 2022; status: completed.
02
Drugs
amifampridine
03
Conditions
Lambert-Eaton myasthenic syndrome (LEMS)
Beyond the preview
Go deeper on jRCT2031210552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210552.